PRGN-3007 (UltraCAR-T)

About Precigen

Precigen is a commercial-stage biopharmaceutical company focused on developing precision gene and cell therapies for immuno-oncology, autoimmune disorders, and infectious diseases. The company achieved a critical inflection point with the FDA approval of PAPZIMEOS in August 2025 for recurrent respiratory papillomatosis (RRP). Its strategy is built on two proprietary technology platforms—AdenoVerse® for viral vector gene delivery and UltraCAR-T® for next-generation cell therapy—designed to overcome key limitations in the field and create a sustainable pipeline of advanced therapeutics.

Therapeutic Areas